What Blue Ox Healthcare Partners does

Blue Ox Healthcare Partners, LLC is a New York-based private equity investment firm founded in 2009 that specializes exclusively in growth-stage, commercial-ready healthcare companies applying technology-enabled innovation to precision health, healthcare delivery, and affordability. The firm invests across three active portfolio companies — Sera Prognostics (proteomic diagnostics for preterm birth risk), Epic Sciences (liquid biopsy for individualized cancer drug selection), and Gemelli Biotech (precision diagnostics for GI diseases) — alongside a historical roster of seven exited or inactive investments.

The current leadership team was assembled in 2017 and consists of four senior members: Charles D. Kennedy, MD (CEO/Managing Partner; former C-level executive at Aetna, Anthem, WellPoint, and Blue Shield of California), Oded Levy (President/Managing Partner; 30+ years in healthcare PE and capital markets), John A. Neczesny (COO/Managing Partner; former Bear Stearns and Oberon Securities healthcare banker with $170B+ in closed M&A and financing), plus Principal Alex Rogers and Analyst Mary Chelini. Blue Ox differentiates through the operating depth and healthcare-side relationships of this small team, which it leverages to guide portfolio companies through commercialization, reimbursement, and adoption challenges.

The firm generates returns through standard private equity economics — management fees and carried interest on funds — and since 2017 has led over $200 million of equity investments, of which more than $85 million has been invested and committed directly by Blue Ox. Deal sourcing is network-driven rather than channel-driven, with strategic capital partners (notably Anthem, which co-led the $100M Series E for Sera Prognostics in April 2021) supplementing the firm's financial investor base. Blue Ox does not publish financials, charge product pricing, or operate as a technology vendor; it is a boutique specialist investor in the U.S. healthcare market.

Name

Blue Ox Healthcare Partners

Legal name

Blue Ox Healthcare Partners, LLC

Website

https://blueoxhcp.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

Blue Ox Healthcare Partners is a New York-based, healthcare-specialist private equity firm founded in 2009 that invests growth capital in commercial-ready companies advancing precision health, healthcare delivery, and affordability, currently active in Sera Prognostics, Epic Sciences, and Gemelli Biotech.

Ownership category

akta.pro rank

Product category

Healthcare Private Equity

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Healthcare private equity
• Growth-stage healthcare investments
• Precision health investing
• Healthcare venture capital
• Medical innovation funding

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Private Equity Fund Management: Generates returns through management fees and carried interest from private equity investments in healthcare companies. Since 2017, has led over $200 million of equity investments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Blue Ox Healthcare Partners is a private equity investment firm that provides growth capital and strategic/operational guidance to commercial-ready, growth-stage healthcare companies. The firm invests in three core areas—precision health, healthcare delivery, and affordability—and has led over $200 million of equity investments since 2017, including direct commitments of more than $85 million. Current active portfolio companies include Sera Prognostics, Epic Sciences, and Gemelli Biotech.

Product overview

Blue Ox Healthcare Partners is a private equity investment firm that does not offer standalone products or services to end customers. The firm provides growth capital, strategic guidance, and operational expertise to commercial-stage healthcare companies. The company focuses its investments on three core areas: Precision Health, Healthcare Delivery, and Affordability. Its current portfolio includes Sera Prognostics (proteomic diagnostic platform for preterm birth risk), Epic Sciences (liquid biopsy platform for cancer drug selection), and Gemelli Biotech (precision diagnostics for GI diseases).

Differentiator

Problem solved

Functional benefit

Products and services

• Growth-Stage Healthcare Private Equity Investment Provides growth-stage equity capital to commercial-ready healthcare companies in precision health, healthcare delivery, and affordability. Since 2017, Blue Ox has led over $200 million of equity investments, including more than $85 million committed directly by the firm, with current portfolio companies Sera Prognostics, Epic Sciences, and Gemelli Biotech.
• Strategic and Operational Advisory for Portfolio Companies Active, hands-on strategic and operational guidance provided to portfolio companies to help them navigate commercialization, reimbursement, and adoption. Includes board representation, senior-operator mentorship, and use of the firm's professional and healthcare industry relationships to optimize deployment, reimbursement, and utilization.
• Healthcare Coverage and Reimbursement Strategy Consulting Consulting services for healthcare companies developing coverage and reimbursement-based go-to-market strategies. Evidenced by the August 2020 consulting agreement with Obalon Therapeutics to support commercialization of the Obalon Balloon System for weight loss.

Quantifiable outcome

• $54 million reduction in total costs demonstrated by PreTRM test-and-treat strategy in analyzed population
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Obalon Therapeutics, Inc.supportingOthers · 13 August 2020Blue Ox entered a consulting agreement with Obalon Therapeutics to provide consulting services including developing and implementing an effective coverage and reimbursement-based go-to-market strategy for the Obalon Balloon System for weight loss.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Town Hall Ventures: Healthcare-focused venture and growth firm investing in companies serving underserved populations and value-based care. Comparable scale and vertical specialization in healthcare delivery innovation.
• Vivo Capital: Healthcare-specialist private equity firm investing across diagnostics, devices, and services globally. Co-invested with Blue Ox on the Sera Prognostics Series E, indicating directly comparable deal focus.
• Longitude Capital: Healthcare-specialist growth equity firm investing in commercial-stage life sciences and healthcare services. Comparable vertical focus, fund size, and growth-stage orientation.
• HealthQuest Capital: Mid-sized healthcare growth equity firm with a diagnostics, devices, and tech-enabled services focus. Directly comparable in stage focus, sector specialization, and target check size.
• Health Catalyst Capital Partners: Smaller healthcare-focused growth equity firm investing in commercial-stage tech-enabled healthcare companies. Closest boutique-scale analog to Blue Ox in stage, focus, and check size.
• SV Health Investors: Healthcare-specialist growth equity and venture firm with deep diagnostics and biotech expertise. Closest comparable in vertical specialization, stage focus, and team-driven investment model.

Broad incumbents

• Summit Partners: Large growth equity firm with a long-standing healthcare and life sciences practice. Direct competitor for healthcare growth deals and a frequent co-investor in the same rounds Blue Ox targets.
• New Mountain Capital: Large healthcare-focused private equity firm with a dedicated healthcare services and tech-enabled care strategy. Competes with Blue Ox for growth-stage healthcare delivery and affordability deals at a much larger check size.
• Welsh, Carson, Anderson & Stowe: One of the largest dedicated healthcare growth equity firms in the US with multi-billion AUM. Direct competitor for growth-stage healthcare deals and a natural alternative LP would consider alongside Blue Ox.

Others

• Anthem Investment Management: Strategic LP and corporate venture arm of a major payor that co-led Sera Prognostics with Blue Ox. Not a direct PE competitor but a critical strategic capital partner and a model for future payor-led co-investment platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/blue-ox-healthcare-partners

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blue Ox Healthcare Partners